Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.IGAP · Entity 8422 | Director | June 01, 2017 | June 09, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date June 01, 2017 · Filed June 09, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 22,727 |
Reported balance
After 2017-06-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-01 · Grant · Acquired 22,727 · Balance 22,727 F1: The restricted stock units do not have a conversion or exercise price. The reporting person's original Form 4 included a conversion price of $1.98. F2: The restricted stock units are scheduled to vest on June 1, 2018, assuming continued service as a director through and on such date. F3: After June 1, 2018, the common stock underlying the restricted stock units may be issued on such date as the reporting person elects or upon termination of their service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units do not have a conversion or exercise price. The reporting person's original Form 4 included a conversion price of $1.98.
F2: The restricted stock units are scheduled to vest on June 1, 2018, assuming continued service as a director through and on such date.
F3: After June 1, 2018, the common stock underlying the restricted stock units may be issued on such date as the reporting person elects or upon termination of their service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2017 Filed Jun 6, 2017 17:56 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantRestricted Stock Units · Derivative | 22,727 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001178913-17-001725 · zk1720093.xml · derivative · entry 2 SCHWARTZ REVAN · CIK 0001690043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock, par value $0.001 per share · 22,727 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units are scheduled to vest on June 1, 2018, assuming continued service as a director through and on such date. F3 · derivative.expiration_date: The common stock underlying the restricted stock units may be issued on such date as the reporting person elects or upon termination of their service with the Issuer. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 17:56 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 14,894 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001178913-17-001725 · zk1720093.xml · derivative · entry 1 SCHWARTZ REVAN · CIK 0001690043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,894 Underlying: Common Stock, par value $0.001 per share · 14,894 shares Expires 2027-06-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over a one year period commencing on June 1, 2017. Read SEC document |
| June 01, 2017 Filed Jun 9, 2017 11:21 UTC Amendment | Glucotrack, Inc. IGAP · Entity 8422 | GrantRestricted Stock Units · Derivative | 22,727 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001178913-17-001782 · a1720119.xml · derivative · entry 1 SCHWARTZ REVAN · CIK 0001690043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock, par value $0.001 per share · 22,727 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units do not have a conversion or exercise price. The reporting person's original Form 4 included a conversion price of $1.98. F2 · derivative.exercise_date: The restricted stock units are scheduled to vest on June 1, 2018, assuming continued service as a director through and on such date. F3 · derivative.expiration_date: After June 1, 2018, the common stock underlying the restricted stock units may be issued on such date as the reporting person elects or upon termination of their service with the Issuer. Read SEC document |
| November 15, 2016 Filed Nov 15, 2016 17:51 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOptions (Right to Buy) · Derivative | 26,666 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001178913-16-006960 · zk1619216.xml · derivative · entry 1 SCHWARTZ REVAN · CIK 0001690043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,666 Underlying: Common Stock, par value $0.001 per share · 26,666 shares Expires 2026-11-15 F1 · derivative.exercise_date: The options will vest in 8 equal quarterly installments with the first installment vesting on February 15, 2017 subject to the continued service of the Reporting Person as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.